ArticleThe Journal of investigative dermatology2021
Characterization of PCSK9 in the Blood and Skin of Psoriasis.
Open access · bronzeAbstract read
In one paragraph
Article in The Journal of investigative dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Statin therapy upregulates arachidonic acid status via enhanced endogenous synthesis in patients with plaque psoriasis.Prostaglandins, leukotrienes, and essential fatty acids · 2022Trial
- From skin to heart: a state-of-the-art perspective on psoriasis-driven cardiovascular comorbidities.Frontiers in immunology · 2026Review
- Psoriasis as a systemic inflammatory disease: an immune set-point framework for comorbidities and relapse.Frontiers in immunology · 2026Review
- Cardiovascular Disease and Psoriasis.Dermatology and therapy · 2026Review
- Cardiovascular disease risk in psoriatic disease: mechanisms and implications for clinical practice.Current opinion in rheumatology · 2025Review
- The causal association between psoriasis and 32 types of cancer: a mendelian randomization study.Discover oncology · 2025Article
- Genetically proxied PCSK9 inhibition is associated with reduced psoriatic arthritis risk.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside.Signal transduction and targeted therapy · 2024Review
- Causal effects of lipid-lowering drugs on skin diseases: a two-sample Mendelian randomization study.Frontiers in medicine · 2024Article
- Metabolic syndrome and psoriatic arthritis: the role of weight loss as a disease-modifying therapy.Therapeutic advances in musculoskeletal disease · 2024Review
- Associations between neighborhood socioeconomic deprivation, IFNγ, and high-density lipoprotein particle size: Data from the Washington, D.C. cardiovascular health and needs assessment.Psychoneuroendocrinology · 2023Observational
- A Route for Investigating Psoriasis: From the Perspective of the Pathological Mechanisms and Therapeutic Strategies of Cancer.International journal of molecular sciences · 2023Review
- Significance of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) for the Monitoring of Treatment Response to Cyclosporine in Patients with Psoriasis.Life (Basel, Switzerland) · 2023Article
- Disease modification in inflammatory skin disorders: opportunities and challenges.Nature reviews. Drug discovery · 2023Review
- Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements-A Narrative Review.Nutrients · 2023Review
- Crosstalk between cholesterol metabolism and psoriatic inflammation.Frontiers in immunology · 2023Review
- Prediction and verification of the effect of psoriasis on coronary heart disease based on artificial neural network.Heliyon · 2022Article
- Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G.JCI insight · 2022Article
- The role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in the pathophysiology of psoriasis and systemic lupus erythematosus.Postepy dermatologii i alergologii · 2022Review
- Transcriptional Basis of Psoriasis from Large Scale Gene Expression Studies: The Importance of Moving towards a Precision Medicine Approach.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 1 country.
Michael S GarshickCenter for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA; Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA.
Yvonne BaumerSection of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Amit K DeySection of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Ryan GrattanLeon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA.
Qimin NgSection of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Heather L TeagueSection of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Zu-Xi YuPathology Core Facility, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Marcus Y ChenSection of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Michael TawilLeon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA.
Tessa J BarrettLeon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA.
James UnderbergCenter for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA.
Edward A FisherCenter for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA; Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA.
James KruegerLaboratory for Investigative Dermatology, Rockefeller University, New York, New York, USA.
Tiffany M Powell-WileyDivision of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Martin P PlayfordPathology Core Facility, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Jeffrey S BergerCenter for the Prevention of Cardiovascular Disease, Department of Medicine, New York University School of Medicine, New York, New York, USA; Leon H. Charney Division of Cardiology, Department of Medicine, New York University School of Medicine, New York, New York, USA; Division of Hematology, Department of Medicine, New York University School of Medicine, New York, New York, USA; Division of Vascular Surgery, Department of Surgery, New York University School of Medicine, New York, New York, USA.
Nehal N MehtaSection of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: nehal.mehta@nih.gov.
National Institutes of Health · USNew York University · USRockefeller University · US
Funding
Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5MHuman Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic disease (PACI) InitiativeZIAHL006193 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SACK, MICHAEL · 2014 to 2023
$25.0MCardiovascular CT Clinical ResearchZIAHL006220 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI CHEN, MARCUS · 2017 to 2025
$22.5MPathology CoreZICHL005904 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI YU, ZU XI · 2010 to 2023
$11.6MCardiovascular Health and Needs Assessment in Washington D.C.ZIAHL006168 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI POWELL-WILEY, TIFFANY · 2013 to 2025
$8.1MInstitutional Career DevelopmentKL2TR001446 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PILLINGER, MICHAEL · 2015 to 2025
$6.7MIn-vitro and Pre-clinical Translational Studies of Inflammation and AtherosclerosisZIAHL006235 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI SACK, MICHAEL · 2018 to 2023
$6.7MNRSA Training CoreTL1TR001447 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MICOLI, KEITH J. · 2015 to 2025
$5.9MTraining Program in Cardiovascular SciencesT32HL098129 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Glenn I Fishman, Ira J Goldberg · 2009 to 2026
$5.9MPilot Study for Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in WomenZIAHL006252 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI POWELL-WILEY, TIFFANY · 2020 to 2025
$5.7MMechanisms of Platelet Activity in Vascular DiseaseR35HL144993 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BERGER, JEFFREY S · 2019 to 2025
$5.5MPlatelet Activity and Vascular Health in Systemic Lupus ErythematosusR01HL139909 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BERGER, JEFFREY S, BUYON, JILL P · 2018 to 2022
$4.3MIntramural NIH HHS ZIA HL006168Intramural NIH HHS ZIA HL006193Intramural NIH HHS ZIA HL006235Intramural NIH HHS ZIA HL006252NCATS NIH HHS KL2 TR001446NCATS NIH HHS TL1 TR001447NCATS NIH HHS UL1 TR001445NHLBI NIH HHS R01 HL114978NHLBI NIH HHS R01 HL139909NHLBI NIH HHS R35 HL144993NHLBI NIH HHS T32 HL098129
Abstract
Mechanisms explaining the link between psoriasis, a proinflammatory condition, and cardiovascular disease are not fully known. PCSK9 is predominantly expressed in hepatocytes as a critical regulator of lipid metabolism, and clinical trials targeting PCSK9 reduce cardiovascular disease. Independent of its role in lipid metabolism, PCSK9 levels associate with endothelial dysfunction and predict cardiovascular events. We used two separate human psoriasis cohorts and the K14-Rac1V12
Indexed as
AdultAnimalsAtherosclerosisCardiovascular DiseasesEndothelium, VascularFemaleHumansMaleMiceMiddle AgedProprotein Convertase 9PsoriasisSkinPCSK9 protein, humanProprotein Convertase 9
Identifiers
What OpenQuestion holds
Texttitle and abstract
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.